Waters Corp WAT

Morningstar Rating
$357.00 −3.54 (0.98%)
View Full Chart

Company Report

Waters Just Diluted Its Exposure to the Drug Manufacturing End Market by Buying BD Assets

Historically, Waters has helped clients perform scientific research by providing analytical instruments, services, and supplies. The company specializes in liquid chromatography and mass spectrometry products (nearly 90% of legacy company sales), which are used primarily by biopharmaceutical firms to analyze a molecule’s structure during the drug discovery, development, and production processes. These tools can also be used in food and environmental quality testing as well as other industrial applications. Waters helps scientists examine the physical properties of various materials through its thermal analysis tools (low-double-digit percentage of sales).

Price vs Fair Value

WAT is trading at a 64% premium.
Price
$357.00
Fair Value
$354.48
Uncertainty
Rpzkcmf
1-Star Price
$449.86
5-Star Price
$118.66
Economic Moat
Cjtp
Capital Allocation
Cbrwghqx

Bulls Say, Bears Say

Bulls

Waters' analytical instruments remain the gold standard in several applications, especially LC-MS for biopharmaceutical firms, where regulations preserve consistent recurring sales for many years.

Bears

With the recent BD merger, Waters could run into integration issues and other challenges while transitioning from a very focused firm to a more diverse one.

News

Articles & Videos

Trading Information

Previous Close Price
$360.54
Day Range
$351.77366.14
52-Week Range
$275.05414.15
Bid/Ask
$325.00 / $384.00
Shares Outstanding
98.19M
Market Cap
$35.05B
Volume/Avg
8 / 1M

Key Statistics

Price/Earnings (Normalized)
26.18
Price/Sales
6.16
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Total Yield
0.04%

Company Profile

Waters sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. In early 2026, Waters merged with BD's life science and diagnostics business, which increased its concentration in diagnostics (versus none now) and discovery-related life science tools.
Sector
Healthcare
Industry
Diagnostics & Research
Stock Style Box
Mid Core
Total Number of Employees
7,900

Competitors

Valuation

Metric
WAT
TMO
A
Price/Earnings (Normalized)
26.1820.2722.35
Price/Book Value
2.283.365.15
Price/Sales
6.163.915.10
Price/Cash Flow
24.3718.1420.04
Price/Earnings
WAT
TMO
A

Financial Strength

Metric
WAT
TMO
A
Quick Ratio
0.970.971.46
Current Ratio
1.791.532.10
Interest Coverage
5.875.3515.47
Quick Ratio
WAT
TMO
A

Profitability

Metric
WAT
TMO
A
Return on Assets (Normalized)
9.95%8.27%13.11%
Return on Equity (Normalized)
17.93%17.01%24.81%
Return on Invested Capital (Normalized)
13.11%10.28%16.82%
Return on Assets
WAT
TMO
A

Diagnostics & Research Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Thermo Fisher Scientific Inc
TMO
NxbwzlcwGll$172B
Danaher Corp
DHR
CqzrwcmbKsfp$126B
Wuxi AppTec Co Ltd ADR
WUXAY
Stbvd$44B
Wuxi AppTec Co Ltd
WUXIF
Ccfqnx$44B
Lonza Group Ltd ADR
LZAGY
FvvdbrhQwqmqf$43B
Lonza Group Ltd
LZAGF
Lhsqb$43B
IDEXX Laboratories Inc
IDXX
XxkgfcffrxXcrr$43B
Agilent Technologies Inc
A
NvqkrflqzJszf$35B
Natera Inc
NTRA
Zsmyljk$32B

Sponsor Center